Investigational Drug Information for Brivanib alaninate
✉ Email this page to a colleague
What is the drug development status for Brivanib alaninate?
Brivanib alaninate is an investigational drug.
There have been 6 clinical trials for Brivanib alaninate.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 5th 2008.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Squamous Cell, and Carcinoma, Renal Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Gynecologic Oncology Group, and Abramson Cancer Center of the University of Pennsylvania.
Summary for Brivanib alaninate
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 492 |
| WIPO Patent Applications | 384 |
| Japanese Patent Applications | 135 |
| Clinical Trial Progress | Phase 3 (2008-02-05) |
| Vendors | 66 |
Recent Clinical Trials for Brivanib alaninate
| Title | Sponsor | Phase |
|---|---|---|
| MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | Zai Lab (Shanghai) Co., Ltd. | Phase 1/Phase 2 |
| Brivanib Metastatic Renal Cell Carcinoma | Abramson Cancer Center of the University of Pennsylvania | Phase 2 |
| Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Brivanib alaninate
Top disease conditions for Brivanib alaninate
Top clinical trial sponsors for Brivanib alaninate
US Patents for Brivanib alaninate
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
